Recent studies indicated that NF-κB is commonly activated in NPC [4, 5], and treatments with NF-κB inhibitors such as dehydroxymethylepoxyquinomicin (DHMEQ) may inhibit the growth and invasion of NPC [2]. Here, NFKB1 is linked to nasopharyngeal carcinoma.